查看文章

The overexpression of heme oxygenase‐1 (HO‐1) contributes to the development of several types of cancers. The inhibition of HO‐1 through imidazole‐based drugs, which is non‐competitive with heme, is a focus of anticancer drug research. We designed the four following novel HO‐1 inhibiting compounds: 2‐(1‐cyclopentyl‐4‐(1H‐imidazol‐4‐yl)butan‐2‐yl)pyrazine (M11), 2‐[(2‐chloro‐3‐methylcyclohexyl)methyl]‐1H‐imidazole (M26), 2‐(2‐phenethyl‐1H‐imidazol‐4‐yl)ethanesulfonamide (M28), and 5‐chloro‐2‐[2‐(2,5‐dihydro‐1H‐imidazol‐2‐yl)propan‐2‐yl]‐1H‐imidazole (M31). All compounds showed a strong binding affinity with HO‐1 in molecular docking studies. The in silico absorption, distribution, metabolism, excretion and toxicity (ADMET) data showed that the compounds would be available orally in an acceptable manner. The bioactivity scores revealed that they were moderately active substances …